Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma

Zhi-Gang Zhu; Lei Chen; Dong-Liu Miao; Yiqi Jin; Qiong Wu

doi:10.3389/fgene.2022.941389

Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma

Front Genet. 2022 Aug 15:13:941389. doi: 10.3389/fgene.2022.941389. eCollection 2022.

Authors

Zhi-Gang Zhu¹, Lei Chen¹, Dong-Liu Miao¹, Yiqi Jin¹, Qiong Wu¹

Affiliation

¹ Department of Intervention and Vascular Surgery, Suzhou Municipal Hospital, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Cancer Medical Center, Suzhou, China.

Abstract

Background: Cellular senescence plays a critical role in the occurrence and development, and immune modulation of cancer. This research primarily investigated the role of senescence-associated genes (SAGs) in the survival and tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC). Methods: From the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) database, the gene expression profiles and clinical data of PDAC samples were downloaded. SAGs in the TCGA cohort were used to build a novel prognostic model and validated in the ICGC cohort. The relationship of signature with the immune landscape, tumor mutational burden (TMB), as well as the sensitivity of different therapies, was explored. Moreover, a nomogram was developed to predict the overall survival of PDAC patients. Results: A prognostic signature was constructed on basis of three SAGs, and patients in the low-risk score group had a longer survival time. The accuracy of the signature to distinguish different score groups was confirmed through principal component analysis (PCA) and the Receiver operator curves curve. The mRNA expression of the three signature genes was also verified in normal pancreatic and PDAC cell lines by RT-qPCR. The signature could independently predict the prognosis of PDAC patients and had broad applicability. Meanwhile, the nomogram predicted that 1- and 3-years survival rates were in good agreement with the observed overall survival rates. Low-risk patients had lower tumor mutational burden, and low-TMB patients had a better prognosis. Low- and high-risk patients exhibit distinct immune cell infiltration and immune checkpoint changes. By further analyzing the risk score, patients in the low-risk group were more responsive to immunotherapy and a variety of commonly used chemotherapeutic drugs. Conclusion: The prognostic signature can well predict the prognosis and assess the possibility of immunotherapy in personalized PDAC treatment.

Keywords: immunotherapy; pancreatic ductal adenocarcinoma; prognostic signature; senescence; tumor microenvironment.